The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins

被引:66
作者
Wagner, BL
Pollio, G
Giangrande, P
Webster, JC
Breslin, M
Mais, DE
Cook, CE
Vedeckis, WV
Cidlowski, JA
McDonnell, DP
机构
[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
[2] NIEHS, Mol Endocrinol Grp, NIH, Res Triangle Pk, NC 27709 USA
[3] Louisiana State Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA
[4] Ligand Pharmaceut Inc, San Diego, CA 92121 USA
[5] Res Triangle Inst, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1210/en.140.3.1449
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have identified two novel compounds (RTI 3021-012 and RTI 3021-022) that demonstrate similar affinities for human progesterone receptor (PR) and display equivalent antiprogestenic activity. As with most antiprogestins, such as RU486, RTI 3021-012, and RTI 3021-022 also bind to the glucocorticoid receptor (GR) with high affinity. Unexpectedly, when compared with RU486, the RTI antagonists manifest significantly less GR antagonist activity. This finding indicates that, with respect to antiglucocorticoid function, receptor binding affinity is not a good predictor of biological activity. We have determined that the lack of a clear correlation between the GR binding affinity of the RTI compounds and their antagonist activity reflects the unique manner in which they modulate GR signaling. Previously, we proposed a two step "active inhibition" model to explain steroid receptor antagonism: 1) competitive inhibition of agonist binding; and 2) competition of the antagonist bound receptor with that activated by agonists for DNA response elements within target gene promoters. Accordingly, we observed that RU486, RTI 3021-012, and RTI 302-1022, when assayed for PR antagonist activity, accomplished both of these steps. Thus, all three compounds are "active antagonists" of PR function. When assayed on GR, however, RU486 alone functioned as an active antagonist. RTI 3021-012 and RTI 3021-022, on the other hand, functioned solely as "competitive antagonists" since they were capable of high affinity GR binding, but the resulting ligand receptor complex was unable to bind DNA. These results have important pharmaceutical implications supporting the use of mechanism based approaches to identify nuclear receptor modulators. Of equal importance, RTI 3021-012 and RTI 3021-022 are two new antiprogestins that may have clinical utility and are likely to be useful as research reagents with which to separate the effects of antiprogestins and antiglucocorticoids in physiological systems.
引用
收藏
页码:1449 / 1458
页数:10
相关论文
共 41 条
[1]   Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression [J].
Alland, L ;
Muhle, R ;
Hou, H ;
Potes, J ;
Chin, L ;
SchreiberAgus, N ;
DePinho, RA .
NATURE, 1997, 387 (6628) :49-55
[2]   Coordinate regulation of glucocorticoid receptor and c-jun gene expression is cell type-specific and exhibits differential hormonal sensitivity for down- and up-regulation [J].
Barrett, TJ ;
Vig, E ;
Vedeckis, WV .
BIOCHEMISTRY, 1996, 35 (30) :9746-9753
[3]   CONTRAGESTION AND OTHER CLINICAL-APPLICATIONS OF RU-486, AN ANTIPROGESTERONE AT THE RECEPTOR [J].
BAULIEU, EE .
SCIENCE, 1989, 245 (4924) :1351-1357
[4]   PROGESTERONE-RECEPTOR MESSENGER-RIBONUCLEIC-ACID AND PROTEIN ARE OVEREXPRESSED IN HUMAN UTERINE LEIOMYOMAS [J].
BRANDON, DD ;
BETHEA, CL ;
STRAWN, EY ;
NOVY, MJ ;
BURRY, KA ;
HARRINGTON, MS ;
ERICKSON, TE ;
WARNER, C ;
KEENAN, EJ ;
CLINTON, GM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 169 (01) :78-85
[5]  
CARROLL RS, 1993, CANCER RES, V53, P1312
[6]   SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers [J].
Chen, JD ;
Umesono, K ;
Evans, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7567-7571
[7]  
CLARK JH, 1979, FEMALE SEX STEROIDS, V14
[8]   PROGESTIN REGULATION OF CELLULAR PROLIFERATION [J].
CLARKE, CL ;
SUTHERLAND, RL .
ENDOCRINE REVIEWS, 1990, 11 (02) :266-301
[9]   THE GROWTH-INHIBITION OF HUMAN BREAST-CANCER CELLS BY A NOVEL SYNTHETIC PROGESTIN INVOLVES THE INDUCTION OF TRANSFORMING GROWTH-FACTOR-BETA [J].
COLLETTA, AA ;
WAKEFIELD, LM ;
HOWELL, FV ;
DANIELPOUR, D ;
BAUM, M ;
SPORN, MB .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (01) :277-283
[10]   NOVEL ESTROGEN RESPONSE ELEMENTS IDENTIFIED BY GENETIC SELECTION IN YEAST ARE DIFFERENTIALLY RESPONSIVE TO ESTROGENS AND ANTIESTROGENS IN MAMMALIAN-CELLS [J].
DANA, SL ;
HOENER, PA ;
WHEELER, DA ;
LAWRENCE, CB ;
MCDONNELL, DP .
MOLECULAR ENDOCRINOLOGY, 1994, 8 (09) :1193-1207